Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 1, 2010, Pages 3-19

  Fanjul Fernández, Miriam ^a   Folgueras, Alicia R ^a   Cabrera, Sandra ^a   López Otín, Carlos ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Cancer; Cardiovascular disease; Degradome; Polymorphism; Protease

Indexed keywords

COLLAGENASE; FURIN; GELATINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 23A; MATRIX METALLOPROTEINASE 23B; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 28; PROTEINASE; STAT PROTEIN; STROMELYSIN; STROMELYSIN 3; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL MEMBRANE; ENZYME ACTIVITY; ENZYME ANALYSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC ORGANIZATION; GENETIC POLYMORPHISM; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; DISEASE; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MATRIX METALLOPROTEINASES; MICE; MODELS, ANIMAL;

ANIMALIA;

EID: 77149137406     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.07.004     Document Type: Review

References (232)

1. Gomis-Ruth F.X. Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 2009.
2. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
3. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
4. Rowe R.G., Weiss S.J. Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18:560-574.
5. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6:480-498.
6. López-Otín C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
7. Folgueras A.R., Pendas A.M., Sanchez L.M., Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48:411-424.
8. Limb G.A., Matter K., Murphy G., Cambrey A.D., Bishop P.N., Morris G.E., Khaw P.T. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am. J. Pathol. 2005, 166:1555-1563.
9. Ruta A., Mark B., Edward B., Jawaharlal P., Jianliang Z. Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp. Lung Res. 2009, 35:59-75.
10. Luo D., Mari B., Stoll I., Anglard P. Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. J. Biol. Chem. 2002, 277:25527-25536.
11. Cuadrado E., Rosell A., Borrell-Pages M., Garcia-Bonilla L., Hernandez-Guillamon M., Ortega-Aznar A., Montaner J. Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J. Cereb. Blood Flow Metab. 2009, 29:398-410.
12. Tester A.M., Cox J.H., Connor A.R., Starr A.E., Dean R.A., Puente X.S., Lopez-Otin C., Overall C.M. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2007, 2:e312.
13. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370:555-557.
14. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
15. Overall C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 2002, 22:51-86.
16. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol. 1997, 15:511-518.
17. Stolow M.A., Bauzon D.D., Li J., Sedgwick T., Liang V.C., Sang Q.A., Shi Y.B. Identification and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development. Mol. Biol. Cell 1996, 7:1471-1483.
18. Barksby H.E., Milner J.M., Patterson A.M., Peake N.J., Hui W., Robson T., Lakey R., Middleton J., Cawston T.E., Richards C.D., Rowan A.D. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. 2006, 54:3244-3253.
19. Geurts N., Martens E., Van Aelst I., Proost P., Opdenakker G., Van den Steen P.E. Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 2008, 47:2689-2699.
20. Shapiro S.D., Kobayashi D.K., Ley T.J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 1993, 268:23824-23829.
21. Hou P., Troen T., Ovejero M.C., Kirkegaard T., Andersen T.L., Byrjalsen I., Ferreras M., Sato T., Shapiro S.D., Foged N.T., Delaisse J.M. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 2004, 34:37-47.
22. Pendás A.M., Knauper V., Puente X.S., Llano E., Mattei M.G., Apte S., Murphy G., López-Otín C. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J. Biol. Chem. 1997, 272:4281-4286.
23. Kolb C., Mauch S., Peter H.H., Krawinkel U., Sedlacek R. The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol. Lett. 1997, 57:83-88.
24. Stracke J.O., Hutton M., Stewart M., Pendas A.M., Smith B., Lopez-Otin C., Murphy G., Knauper V. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J. Biol. Chem. 2000, 275:14809-14816.
25. Llano E., Pendas A.M., Knauper V., Sorsa T., Salo T., Salido E., Murphy G., Simmer J.P., Bartlett J.D., Lopez-Otin C. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 1997, 36:15101-15108.
26. Lu Y., Papagerakis P., Yamakoshi Y., Hu J.C., Bartlett J.D., Simmer J.P. Functions of KLK4 and MMP-20 in dental enamel formation. Biol. Chem. 2008, 389:695-700.
27. Yang M., Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J. Biol. Chem. 1998, 273:17893-17900.
28. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., Pennington C.J., Bourgoin P., Edwards D.R., Yong V.W. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
29. Uria J.A., Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000, 60:4745-4751.
30. Wang W.S., Chen P.M., Wang H.S., Liang W.Y., Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006, 27:1113-1120.
31. McGuire J.K., Li Q., Parks W.C. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. 2003, 162:1831-1843.
32. Li Q., Park P.W., Wilson C.L., Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
33. Zhao Y.G., Xiao A.Z., Park H.I., Newcomer R.G., Yan M., Man Y.G., Heffelfinger S.C., Sang Q.X. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res. 2004, 64:590-598.
34. Qiu W., Bai S.X., Zhao M.R., Wu X.Q., Zhao Y.G., Sang Q.X., Wang Y.L. Spatio-temporal expression of matrix metalloproteinase-26 in human placental trophoblasts and fetal red cells during normal placentation. Biol. Reprod. 2005, 72:954-959.
35. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
36. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002, 100:1160-1167.
37. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
38. Rio M.C. From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie 2005, 87:299-306.
39. Motrescu E.R., Blaise S., Etique N., Messaddeq N., Chenard M.P., Stoll I., Tomasetto C., Rio M.C. Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 2008, 27:6347-6355.
40. Ahokas K., Lohi J., Lohi H., Elomaa O., Karjalainen-Lindsberg M.L., Kere J., Saarialho-Kere U. Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. Gene 2002, 301:31-41.
41. Lohi J., Wilson C.L., Roby J.D., Parks W.C. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J. Biol. Chem. 2001, 276:10134-10144.
42. Werner S.R., Dotzlaf J.E., Smith R.C. MMP-28 as a regulator of myelination. BMC Neurosci. 2008, 9:83.
43. Zucker S., Pei D., Cao J., Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol. 2003, 54:1-74.
44. Gingras D., Bousquet-Gagnon N., Langlois S., Lachambre M.P., Annabi B., Beliveau R. Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 2001, 507:231-236.
45. Sounni N.E., Roghi C., Chabottaux V., Janssen M., Munaut C., Maquoi E., Galvez B.G., Gilles C., Frankenne F., Murphy G., Foidart J.M., Noel A. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 2004, 279:13564-13574.
46. Uekita T., Itoh Y., Yana I., Ohno H., Seiki M. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J. Cell Biol. 2001, 155:1345-1356.
47. Sounni N.E., Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005, 87:329-342.
48. Uchibori M., Nishida Y., Nagasaka T., Yamada Y., Nakanishi K., Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int. J. Oncol. 2006, 28:33-42.
49. Ip Y.C., Cheung S.T., Fan S.T. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol. Carcinog. 2007, 46:225-230.
50. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., Stack M.S., Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
51. Bartolome R.A., Ferreiro S., Miquilena-Colina M.E., Martinez-Prats L., Soto-Montenegro M.L., Garcia-Bernal D., Vaquero J.J., Agami R., Delgado R., Desco M., Sanchez-Mateos P., Teixido J. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am. J. Pathol. 2009, 174:602-612.
52. Puente X.S., Pendas A.M., Llano E., Velasco G., Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 1996, 56:944-949.
53. Pei D. Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res. 1999, 9:291-303.
54. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 2004, 279:10042-10051.
55. Velasco G., Cal S., Merlos-Suarez A., Ferrando A.A., Alvarez S., Nakano A., Arribas J., Lopez-Otin C. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000, 60:877-882.
56. Sohail A., Sun Q., Zhao H., Bernardo M.M., Cho J.A., Fridman R. MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev. 2008, 27:289-302.
57. Velasco G., Pendas A.M., Fueyo A., Knauper V., Murphy G., Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 1999, 274:4570-4576.
58. Massova I., Kotra L.P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12:1075-1095.
59. Huxley-Jones J., Clarke T.K., Beck C., Toubaris G., Robertson D.L., Boot-Handford R.P. The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio. BMC Evol. Biol. 2007, 7:63.
60. Page-McCaw A. Remodeling the model organism: matrix metalloproteinase functions in invertebrates. Semin. Cell Dev. Biol. 2008, 19:14-23.
61. Angerer L., Hussain S., Wei Z., Livingston B.T. Sea urchin metalloproteases: a genomic survey of the BMP-1/tolloid-like. MMP and ADAM families, Dev. Biol. 2006, 300:267-281.
62. Puente X.S., Gutierrez-Fernandez A., Ordonez G.R., Hillier L.W., Lopez-Otin C. Comparative genomic analysis of human and chimpanzee proteases. Genomics 2005, 86:638-647.
63. Puente X.S., Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res. 2004, 14:609-622.
64. Fu L., Das B., Mathew S., Shi Y.B. Genome-wide identification of Xenopus matrix metalloproteinases: conservation and unique duplications in amphibians. BMC Genomics 2009, 10:81.
65. Ordonez G.R., Hillier L.W., Warren W.C., Grutzner F., Lopez-Otin C., Puente X.S. Loss of genes implicated in gastric function during platypus evolution. Genome Biol. 2008, 9:R81.
66. Balbin M., Fueyo A., Knauper V., Lopez J.M., Alvarez J., Sanchez L.M., Quesada V., Bordallo J., Murphy G., Lopez-Otin C. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 2001, 276:10253-10262.
67. Huxley-Jones J., Robertson D.L., Boot-Handford R.P. On the origins of the extracellular matrix in vertebrates. Matrix Biol. 2007, 26:2-11.
68. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 1996, 271:1544-1550.
69. Lopez-Otin C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283:30433-30437.
70. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 2007, 211:19-26.
71. Vincenti M.P., Brinckerhoff C.E. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you?. J. Cell Physiol. 2007, 213:355-364.
72. Overall C.M., López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2:657-672.
73. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008, 40:1362-1378.
74. Wang X., Bi Z., Chu W., Wan Y. IL-1 receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1 expression in UVA-irradiated human fibroblasts induced by culture medium from UVB-irradiated human skin keratinocytes. Int. J. Mol. Med. 2005, 16:1117-1124.
75. Chakraborti S., Mandal M., Das S., Mandal A., Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 2003, 253:269-285.
76. Kumar D., Ray A., Ray B.K. Transcriptional synergy mediated by SAF-1 and AP-1: critical role of N-terminal polyalanine and two zinc finger domains of SAF-1. J. Biol. Chem. 2009, 284:1853-1862.
77. Yan J., Erdem H., Li R., Cai Y., Ayala G., Ittmann M., Yu-Lee L.Y., Tsai S.Y., Tsai M.J. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008, 68:5460-5468.
78. Qin L., Liao L., Redmond A., Young L., Yuan Y., Chen H., O'Malley B.W., Xu J. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol. Cell. Biol. 2008, 28:5937-5950.
79. Wu J.Y., Lu H., Sun Y., Graham D.Y., Cheung H.S., Yamaoka Y. Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res. 2006, 66:5111-5120.
80. Westermarck J., Seth A., Kahari V.M. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997, 14:2651-2660.
81. Vincenti M.P., Brinckerhoff C.E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002, 4:157-164.
82. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., Mornet D. l-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 2008, 172:1509-1519.
83. Wang Z., Kong D., Banerjee S., Li Y., Adsay N.V., Abbruzzese J., Sarkar F.H. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67:11377-11385.
84. Elliott S.F., Coon C.I., Hays E., Stadheim T.A., Vincenti M.P. Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum. 2002, 46:3230-3239.
85. Sato H., Seiki M. Regulatory mechanism of 92kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8:395-405.
86. Li W.X. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008, 18:545-551.
87. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25:1195-1204.
88. Song Y., Qian L., Song S., Chen L., Zhang Y., Yuan G., Zhang H., Xia Q., Hu M., Yu M., Shi M., Jiang Z., Guo N. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol. 2008, 45:137-143.
89. Zhao X., Nozell S., Ma Z., Benveniste E.N. The interferon-stimulated gene factor 3 complex mediates the inhibitory effect of interferon-beta on matrix metalloproteinase-9 expression. FEBS J. 2007, 274:6456-6468.
90. Gustavson M.D., Crawford H.C., Fingleton B., Matrisian L.M. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol. Carcinog. 2004, 41:125-139.
91. Crawford H.C., Fingleton B., Gustavson M.D., Kurpios N., Wagenaar R.A., Hassell J.A., Matrisian L.M. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell. Biol. 2001, 21:1370-1383.
92. Takahashi M., Tsunoda T., Seiki M., Nakamura Y., Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002, 21:5861-5867.
93. Mengshol J.A., Vincenti M.P., Brinckerhoff C.E. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 2001, 29:4361-4372.
94. Jimenez M.J., Balbin M., Alvarez J., Komori T., Bianco P., Holmbeck K., Birkedal-Hansen H., Lopez J.M., Lopez-Otin C. A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. J. Cell Biol. 2001, 155:1333-1344.
95. Ortega N., Behonick D.J., Werb Z. Matrix remodeling during endochondral ossification. Trends Cell Biol. 2004, 14:86-93.
96. Uria J.A., Jimenez M.G., Balbin M., Freije J.M., Lopez-Otin C. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J. Biol. Chem. 1998, 273:9769-9777.
97. Van Themsche C., Mathieu I., Parent S., Asselin E. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J. Biol. Chem. 2007, 282:4794-4802.
98. Kuo Y.C., Su C.H., Liu C.Y., Chen T.H., Chen C.P., Wang H.S. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int. J. Cancer 2009.
99. Yuan W., Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 2001, 276:38502-38510.
100. Leivonen S.K., Chantry A., Hakkinen L., Han J., Kahari V.M. Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J. Biol. Chem. 2002, 277:46338-46346.
101. Chicoine E., Esteve P.O., Robledo O., Van Themsche C., Potworowski E.F., St-Pierre Y. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Commun. 2002, 297:765-772.
102. Shukeir N., Pakneshan P., Chen G., Szyf M., Rabbani S.A. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 2006, 66:9202-9210.
103. Couillard J., Demers M., Lavoie G., St-Pierre Y. The role of DNA hypomethylation in the control of stromelysin gene expression. Biochem. Biophys. Res. Commun. 2006, 342:1233-1239.
104. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
105. Yan C., Wang H., Toh Y., Boyd D.D. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J. Biol. Chem. 2003, 278:2309-2316.
106. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126:321-334.
107. Young D.A., Lakey R.L., Pennington C.J., Jones D., Kevorkian L., Edwards D.R., Cawston T.E., Clark I.M. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res. Ther. 2005, 7:R503-R512.
108. Martens J.H., Verlaan M., Kalkhoven E., Zantema A. Cascade of distinct histone modifications during collagenase gene activation. Mol. Cell. Biol. 2003, 23:1808-1816.
109. Kim M.K., Shin J.M., Eun H.C., Chung J.H. The role of p300 histone acetyltransferase in UV-induced histone modifications and MMP-1 gene transcription. PLoS ONE 2009, 4:e4864.
110. Ma Z., Shah R.C., Chang M.J., Benveniste E.N. Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol. Cell. Biol. 2004, 24:5496-5509.
111. Zhao X., Benveniste E.N. Transcriptional activation of human matrix metalloproteinase-9 gene expression by multiple co-activators. J. Mol. Biol. 2008, 383:945-956.
112. Robert I., Aussems M., Keutgens A., Zhang X., Hennuy B., Viatour P., Vanstraelen G., Merville M.P., Chapelle J.P., de Leval L., Lambert F., Dejardin E., Gothot A., Chariot A. Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes. Oncogene 2009.
113. Akool el S., Kleinert H., Hamada F.M., Abdelwahab M.H., Forstermann U., Pfeilschifter J., Eberhardt W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell Biol. 2003, 23:4901-4916.
114. Huwiler A., Akool el S., Aschrafi A., Hamada F.M., Pfeilschifter J., Eberhardt W. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J. Biol. Chem. 2003, 278:51758-51769.
115. Iyer V., Pumiglia K., DiPersio C.M. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J. Cell. Sci. 2005, 118:1185-1195.
116. Krishnamurthy P., Rajasingh J., Lambers E., Qin G., Losordo D.W., Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ. Res. 2009, 104:e9-e18.
117. Rydziel S., Delany A.M., Canalis E. AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J. Biol. Chem. 2004, 279:5397-5404.
118. Fahling M., Steege A., Perlewitz A., Nafz B., Mrowka R., Persson P.B., Thiele B.J. Role of nucleolin in posttranscriptional control of MMP-9 expression. Biochim. Biophys. Acta 2005, 1731:32-40.
119. Jiang Y., Muschel R.J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res. 2002, 62:1910-1914.
120. Dalmay T., Edwards D.R. MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25:6170-6175.
121. Xia H., Qi Y., Ng S.S., Chen X., Chen S., Ge R., Jiang S., Li G., Chen Y., He M.L., Kung H.F., Lai L., Lin M.C. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 2009.
122. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., Gnyawali S., Shilo S., Nuovo G.J., Sen C.K. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
123. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28:5369-5380.
124. Jones S.W., Watkins G., Le Good N., Roberts S., Murphy C.L., Brockbank S.M., Needham M.R., Read S.J., Newham P. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage 2009, 17:464-472.
125. Martignetti J.A., Aqeel A.A., Sewairi W.A., Boumah C.E., Kambouris M., Mayouf S.A., Sheth K.V., Eid W.A., Dowling O., Harris J., Glucksman M.J., Bahabri S., Meyer B.F., Desnick R.J. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. 2001, 28:261-265.
126. Zankl A., Bonafe L., Calcaterra V., Di Rocco M., Superti-Furga A. Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2. Clin. Genet. 2005, 67:261-266.
127. Zankl A., Pachman L., Poznanski A., Bonafe L., Wang F., Shusterman Y., Fishman D.A., Superti-Furga A. Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. J. Bone Miner. Res. 2007, 22:329-333.
128. Kennedy A.M., Inada M., Krane S.M., Christie P.T., Harding B., Lopez-Otin C., Sanchez L.M., Pannett A.A., Dearlove A., Hartley C., Byrne M.H., Reed A.A., Nesbit M.A., Whyte M.P., Thakker R.V. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO). J. Clin. Invest. 2005, 115:2832-2842.
129. Kim J.W., Simmer J.P., Hart T.C., Hart P.S., Ramaswami M.D., Bartlett J.D., Hu J.C. MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J. Med. Genet. 2005, 42:271-275.
130. Papagerakis P., Lin H.K., Lee K.Y., Hu Y., Simmer J.P., Bartlett J.D., Hu J.C. Premature stop codon in MMP20 causing amelogenesis imperfecta. J. Dent. Res. 2008, 87:56-59.
131. Ozdemir D., Hart P.S., Ryu O.H., Choi S.J., Ozdemir-Karatas M., Firatli E., Piesco N., Hart T.C. MMP20 active-site mutation in hypomaturation amelogenesis imperfecta. J. Dent. Res. 2005, 84:1031-1035.
132. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
133. Viloria C.G., Obaya A.J., Moncada-Pazos A., Llamazares M., Astudillo A., Capella G., Cal S., Lopez-Otin C. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 2009, 69:4926-4934.
134. Zhu Y., Spitz M.R., Lei L., Mills G.B., Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001, 61:7825-7829.
135. Woo M., Park K., Nam J., Kim J.C. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J. Gastroenterol. Hepatol. 2007, 22:1064-1070.
136. Przybylowska K., Kluczna A., Zadrozny M., Krawczyk T., Kulig A., Rykala J., Kolacinska A., Morawiec Z., Drzewoski J., Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res. Treat. 2006, 95:65-72.
137. Six L., Grimm C., Leodolter S., Tempfer C., Zeillinger R., Sliutz G., Speiser P., Reinthaller A., Hefler L.A. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol. Oncol. 2006, 100:506-510.
138. Ye S., Dhillon S., Turner S.J., Bateman A.C., Theaker J.M., Pickering R.M., Day I., Howell W.M. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 2001, 61:1296-1298.
139. Checa M., Ruiz V., Montano M., Velazquez-Cruz R., Selman M., Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum. Genet. 2008, 124:465-472.
140. Okamoto K., Mimura K., Murawaki Y., Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastroenterol. Hepatol. 2005, 20:1102-1108.
141. Yu C., Zhou Y., Miao X., Xiong P., Tan W., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004, 64:7622-7628.
142. Zhou Y., Yu C., Miao X., Wang Y., Tan W., Sun T., Zhang X., Xiong P., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005, 26:1117-1121.
143. Harendza S., Lovett D.H., Panzer U., Lukacs Z., Kuhnl P., Stahl R.A. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J. Biol. Chem. 2003, 278:20490-20499.
144. Fang S., Jin X., Wang R., Li Y., Guo W., Wang N., Wang Y., Wen D., Wei L., Zhang J. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005, 26:481-486.
145. Ghilardi G., Biondi M.L., Caputo M., Leviti S., DeMonti M., Guagnellini E., Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002, 8:3820-3823.
146. Vairaktaris E., Yapijakis C., Vasiliou S., Derka S., Nkenke E., Serefoglou Z., Vorris E., Vylliotis A., Ragos V., Neukam F.W., Patsouris
147. Djuric T., Zivkovic M., Radak D., Jekic D., Radak S., Stojkovic L., Raicevic R., Stankovic A., Alavantic D. Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid atherosclerosis. Clin. Biochem. 2008, 41:1326-1329.
148. Mattey D.L., Nixon N.B., Dawes P.T., Ollier W.E., Hajeer A.H. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun. 2004, 5:147-149.
149. Jormsjo S., Whatling C., Walter D.H., Zeiher A.M., Hamsten A., Eriksson P. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb. Vasc. Biol. 2001, 21:1834-1839.
150. Kubben F.J., Sier C.F., Meijer M.J., van den Berg M., van der Reijden J.J., Griffioen G., van de Velde C.J., Lamers C.B., Verspaget H.W. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br. J. Cancer 2006, 95:744-751.
151. Singh H., Jain M., Mittal B. MMP-7 (- 181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol. Oncol. 2008, 110:71-75.
152. Vairaktaris E., Serefoglou Z., Yapijakis C., Vylliotis A., Nkenke E., Derka S., Vassiliou S., Avgoustidis D., Neukam F.W., Patsouris E. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res. 2007, 27:2493-2498.
153. Zhang J., Jin X., Fang S., Wang R., Li Y., Wang N., Guo W., Wang Y., Wen D., Wei L., Dong Z., Kuang G. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005, 26:1748-1753.
154. Wang H., Parry S., Macones G., Sammel M.D., Ferrand P.E., Kuivaniemi H., Tromp G., Halder I., Shriver M.D., Romero R., Strauss J.F. Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum. Mol. Genet. 2004, 13:2659-2669.
155. Decock J., Long J.R., Laxton R.C., Shu X.O., Hodgkinson C., Hendrickx W., Pearce E.G., Gao Y.T., Pereira A.C., Paridaens R., Zheng W., Ye S. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007, 67:10214-10221.
156. Gonzalez-Arriaga P., Lopez-Cima M.F., Fernandez-Somoano A., Pascual T., Marron M.G., Puente X.S., Tardon A. Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer 2008, 8:378.
157. Balbin M., Fueyo A., Tester A.M., Pendas A.M., Pitiot A.S., Astudillo A., Overall C.M., Shapiro S.D., Lopez-Otin C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 2003, 35:252-257.
158. Gutierrez-Fernandez A., Fueyo A., Folgueras A.R., Garabaya C., Pennington C.J., Pilgrim S., Edwards D.R., Holliday D.L., Jones J.L., Span P.N., Sweep F.C., Puente X.S., Lopez-Otin C. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008, 68:2755-2763.
159. Korpi J.T., Kervinen V., Maklin H., Vaananen A., Lahtinen M., Laara E., Ristimaki A., Thomas G., Ylipalosaari M., Astrom P., Lopez-Otin C., Sorsa T., Kantola S., Pirila E., Salo T. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br. J. Cancer 2008, 98:766-775.
160. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 2003, 81:321-326.
161. Jones G.T., Phillips V.L., Harris E.L., Rossaak J.I., van Rij A.M. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J. Vasc. Surg. 2003, 38:1363-1367.
162. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb. Vasc. Biol. 2004, 24:1479-1484.
163. Kader A.K., Liu J., Shao L., Dinney C.P., Lin J., Wang Y., Gu J., Grossman H.B., Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin. Cancer Res. 2007, 13:2614-2620.
164. Fiotti N., Altamura N., Fisicaro M., Carraro N., Adovasio R., Sarra V.M., Uxa L., Guarnieri G., Baxter B.T., Giansante C. MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis 2005, 182:287-292.
165. Fiotti N., Zivadinov R., Altamura N., Nasuelli D., Bratina A., Tommasi M.A., Bosco A., Locatelli L., Grop A., Cazzato G., Guarnieri G., Giansante C., Zorzon M. MMP-9 microsatellite polymorphism and multiple sclerosis. J. Neuroimmunol. 2004, 152:147-153.
166. Peters D.G., Kassam A., St Jean P.L., Yonas H., Ferrell R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999, 30:2612-2616.
167. Fiotti N., Pedio M., Battaglia Parodi M., Altamura N., Uxa L., Guarnieri G., Giansante C., Ravalico G. MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration. Genet. Med. 2005, 7:272-277.
168. Inada M., Wang Y., Byrne M.H., Rahman M.U., Miyaura C., López-Otín C., Krane S.M. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17192-17197.
169. Stickens D., Behonick D.J., Ortega N., Heyer B., Hartenstein B., Yu Y., Fosang A.J., Schorpp-Kistner M., Angel P., Werb Z. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004, 131:5883-5895.
170. Wiseman B.S., Sternlicht M.D., Lund L.R., Alexander C.M., Mott J., Bissell M.J., Soloway P., Itohara S., Werb Z. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J. Cell Biol. 2003, 162:1123-1133.
171. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
172. Inoue K., Mikuni-Takagaki Y., Oikawa K., Itoh T., Inada M., Noguchi T., Park J.S., Onodera T., Krane S.M., Noda M., Itohara S. A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J. Biol. Chem. 2006, 281:33814-33824.
173. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., Mankani M., Robey P.G., Poole A.R., Pidoux I., Ward J.M., Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
174. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4052-4057.
175. Caterina J.J., Skobe Z., Shi J., Ding Y., Simmer J.P., Birkedal-Hansen H., Bartlett J.D. Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J. Biol. Chem. 2002, 277:49598-49604.
176. Oh J., Takahashi R., Adachi E., Kondo S., Kuratomi S., Noma A., Alexander D.B., Motoda H., Okada A., Seiki M., Itoh T., Itohara S., Takahashi C., Noda M. Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene 2004, 23:5041-5048.
177. Shi J., Son M.Y., Yamada S., Szabova L., Kahan S., Chrysovergis K., Wolf L., Surmak A., Holmbeck K. Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev. Biol. 2008, 313:196-209.
178. D'Armiento J., DiColandrea T., Dalal S.S., Okada Y., Huang M.T., Conney A.H., Chada K. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell. Biol. 1995, 15:5732-5739.
179. Ha H.Y., Moon H.B., Nam M.S., Lee J.W., Ryoo Z.Y., Lee T.H., Lee K.K., So B.J., Sato H., Seiki M., Yu D.Y. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res. 2001, 61:984-990.
180. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
181. Gorrin-Rivas M.J., Arii S., Furutani M., Mizumoto M., Mori A., Hanaki K., Maeda M., Furuyama H., Kondo Y., Imamura M. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin. Cancer Res. 2000, 6:1647-1654.
182. Witty J.P., Lempka T., Coffey R.J., Matrisian L.M. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 1995, 55:1401-1406.
183. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
184. Andarawewa K.L., Boulay A., Masson R., Mathelin C., Stoll I., Tomasetto C., Chenard M.P., Gintz M., Bellocq J.P., Rio M.C. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res. 2003, 63:5844-5849.
185. Pendas A.M., Folgueras A.R., Llano E., Caterina J., Frerard F., Rodriguez F., Astudillo A., Noel A., Birkedal-Hansen H., Lopez-Otin C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell. Biol. 2004, 24:5304-5313.
186. Jost M., Folgueras A.R., Frerart F., Pendas A.M., Blacher S., Houard X., Berndt S., Munaut C., Cataldo D., Alvarez J., Melen-Lamalle L., Foidart J.M., Lopez-Otin C., Noel A. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res. 2006, 66:5234-5241.
187. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 2002, 169:2643-2647.
188. Clements K.M., Price J.S., Chambers M.G., Visco D.M., Poole A.R., Mason R.M. Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum. 2003, 48:3452-3463.
189. Deguchi J.O., Aikawa E., Libby P., Vachon J.R., Inada M., Krane S.M., Whittaker P., Aikawa M. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005, 112:2708-2715.
190. Silence J., Lupu F., Collen D., Lijnen H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb. Vasc. Biol. 2001, 21:1440-1445.
191. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004, 109:1408-1414.
192. Kuzuya M., Nakamura K., Sasaki T., Cheng X.W., Itohara S., Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb. Vasc. Biol. 2006, 26:1120-1125.
193. Agrawal S., Anderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., Sorokin L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1007-1019.
194. Folgueras A.R., Fueyo A., Garcia-Suarez O., Cox J., Astudillo A., Tortorella P., Campestre C., Gutierrez-Fernandez A., Fanjul-Fernandez M., Pennington C.J., Edwards D.R., Overall C.M., Lopez-Otin C. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J. Biol. Chem. 2008, 283:9465-9474.
195. Buhler L.A., Samara R., Guzman E., Wilson C.L., Krizanac-Bengez L., Janigro D., Ethell D.W. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci. 2009, 10:17.
196. Weaver A., Goncalves da Silva A., Nuttall R.K., Edwards D.R., Shapiro S.D., Rivest S., Yong V.W. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 2005, 19:1668-1670.
197. Corry D.B., Rishi K., Kanellis J., Kiss A., Song Lz L.Z., Xu J., Feng L., Werb Z., Kheradmand F. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat. Immunol. 2002, 3:347-353.
198. Greenlee K.J., Corry D.B., Engler D.A., Matsunami R.K., Tessier P., Cook R.G., Werb Z., Kheradmand F. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 2006, 177:7312-7321.
199. Gueders M.M., Balbin M., Rocks N., Foidart J.M., Gosset P., Louis R., Shapiro S., Lopez-Otin C., Noel A., Cataldo D.D. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J. Immunol. 2005, 175:2589-2597.
200. Kassim S.Y., Gharib S.A., Mecham B.H., Birkland T.P., Parks W.C., McGuire J.K. Individual matrix metalloproteinases control distinct transcriptional responses in airway epithelial cells infected with Pseudomonas aeruginosa. Infect. Immun. 2007, 75:5640-5650.
201. Hautamaki R.D., Kobayashi D.K., Senior R.M., Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277:2002-2004.
202. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., Sheppard D., Pardo A., Selman M., Heller R.A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6292-6297.
203. Kruger A. Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biol. Chem. 2009, 390:91-97.
204. Miao X., Yu C., Tan W., Xiong P., Liang G., Lu W., Lin D. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (- 1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res. 2003, 63:3987-3990.
205. Lin S.C., Lo S.S., Liu C.J., Chung M.Y., Huang J.W., Chang K.W. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J. Oral. Pathol. Med. 2004, 33:405-409.
206. Dong D.M., Yao M., Liu B., Sun C.Y., Jiang Y.Q., Wang Y.S. Association between the - 1306C/T polymorphism of matrix metalloproteinase-2 gene and lumbar disc disease in Chinese young adults. Eur. Spine J. 2007, 16:1958-1961.
207. Vairaktaris E., Vassiliou S., Nkenke E., Serefoglou Z., Derka S., Tsigris C., Vylliotis A., Yapijakis C., Neukam F.W., Patsouris E. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur. J. Surg. Oncol. 2008, 34:450-455.
208. D'Armiento J., Dalal S.S., Okada Y., Berg R.A., Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992, 71:955-961.
209. Cheng S., Pollock A.S., Mahimkar R., Olson J.L., Lovett D.H. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006, 20:1898-1900.
210. McCawley L.J., Wright J., LaFleur B.J., Crawford H.C., Matrisian L.M. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am. J. Pathol. 2008, 173:1528-1539.
211. Cabrera S., Gaxiola M., Arreola J.L., Ramirez R., Jara P., D'Armiento J., Richards T., Selman M., Pardo A. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 2007, 39:2324-2338.
212. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
213. Wilson C.L., Heppner K.J., Labosky P.A., Hogan B.L., Matrisian L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1402-1407.
214. Szabova L., Chrysovergis K., Yamada S.S., Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008, 27:3274-3281.
215. Itoh T., Ikeda T., Gomi H., Nakao S., Suzuki T., Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. 1997, 272:22389-22392.
216. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
217. Wielockx B., Lannoy K., Shapiro S.D., Itoh T., Itohara S., Vandekerckhove J., Libert C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat. Med. 2001, 7:1202-1208.
218. McCawley L.J., Crawford H.C., King L.E., Mudgett J., Matrisian L.M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004, 64:6965-6972.
219. Wang M., Qin X., Mudgett J.S., Ferguson T.A., Senior R.M., Welgus H.G. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6885-6889.
220. Wilson C.L., Ouellette A.J., Satchell D.P., Ayabe T., Lopez-Boado Y.S., Stratman J.L., Hultgren S.J., Matrisian L.M., Parks W.C. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286:113-117.
221. Powell W.C., Fingleton B., Wilson C.L., Boothby M., Matrisian L.M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 1999, 9:1441-1447.
222. Dunsmore S.E., Saarialho-Kere U.K., Roby J.D., Wilson C.L., Matrisian L.M., Welgus H.G., Parks W.C. Matrilysin expression and function in airway epithelium. J. Clin. Invest. 1998, 102:1321-1331.
223. Van Lint P., Wielockx B., Puimege L., Noel A., Lopez-Otin C., Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J. Immunol. 2005, 175:7642-7649.
224. Larsen P.H., DaSilva A.G., Conant K., Yong V.W. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 2006, 26:2207-2214.
225. Itoh T., Tanioka M., Matsuda H., Nishimoto H., Yoshioka T., Suzuki R., Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 1999, 17:177-181.
226. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 2002, 110:625-632.
227. Castaneda F.E., Walia B., Vijay-Kumar M., Patel N.R., Roser S., Kolachala V.L., Rojas M., Wang L., Oprea G., Garg P., Gewirtz A.T., Roman J., Merlin D., Sitaraman S.V. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005, 129:1991-2008.
228. Lijnen H.R., Van Hoef B., Vanlinthout I., Verstreken M., Rio M.C., Collen D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler Thromb. Vasc. Biol. 1999, 19:2863-2870.
229. Uchinami H., Seki E., Brenner D.A., D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006, 44:420-429.
230. Rikimaru A., Komori K., Sakamoto T., Ichise H., Yoshida N., Yana I., Seiki M. Establishment of an MT4-MMP-deficient mouse strain representing an efficient tracking system for MT4-MMP/MMP-17 expression in vivo using beta-galactosidase. Genes Cells 2007, 12:1091-1100.
231. Komori K., Nonaka T., Okada A., Kinoh H., Hayashita-Kinoh H., Yoshida N., Yana I., Seiki M. Absence of mechanical allodynia and Abeta-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase. FEBS Lett. 2004, 557:125-128.
232. Manicone A.M., Birkland T.P., Lin M., Betsuyaku T., van Rooijen N., Lohi J., Keski-Oja J., Wang Y., Skerrett S.J., Parks W.C. Epilysin (MMP-28) restrains early macrophage recruitment in Pseudomonas aeruginosa pneumonia. J. Immunol. 2009, 182:3866-3876.